Rain Oncology has reported that the Phase III MANTRA trial of milademetan did not meet the primary endpoint of progression free survival (PFS) by blinded independent central review compared to trabectedin, a standard of care treatment for dedifferentiated (DD) liposarcoma (LPS).

Based on 115 events, the median PFS was 3.6 months for milademetan while it was 2.2 months for trabectedin.

Nausea, thrombocytopenia, anemia, vomiting and neutropenia were the most common treatment emergent adverse events (TEAEs) observed in the milademetan treated group.

Further, Grade 3/4 TEAEs were also observed in the milademetan arm including neutropenia, anemia and thrombocytopenia.

Dose reductions in the milademetan arm and discontinuations in the milademetan arm due to AEs were observed as 44.2% and 11.6%, respectively, compared with trabectedin arm of 29.1% and 19.0%.

Rain Oncology co-founder and CEO Avanish Vellanki said: “We are very disappointed in the outcome of the MANTRA trial, as the results did not closely mirror prior clinical results in patients with DD LPS.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We are truly saddened we will not likely be able to offer patients new treatment options for this challenging disease. However, the quality and robustness of the global MANTRA trial reflects an unambiguous data set. 

“Based on the MANTRA topline results, we will also re-evaluate the path forward for milademetan. We continue to believe that reactivating p53is an important avenue to pursue as part of a treatment strategy across cancer.”

The trial enrolled a total of 175 patients to determine the safety and efficacy of milademetan against trabectedin.

The study’s secondary endpoints included overall survival, objective response rate, PFS by investigator assessment, disease control rate, safety and patient reported outcomes along with duration of response.